theMednet - In light of ZUMA-7 results, would you consider use of CAR-T off-label for a pediatric or AYA patient with relapsed or refractory large B-cell lymphoma?

Topics: Hematologic Malignancies • Pediatric Oncology • Bone Marrow Transplant • Non-Hodgkin Lymphoma • AYA • Hematology • ASH 2021

In light of ZUMA-7 results, would you consider use of CAR-T off-label for a pediatric or AYA patient with relapsed or refractory large B-cell lymphoma?